{"schema_version":"secwatch.filing_event.v1","accession":"0001701478-25-000051","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.185133+00:00","generated_at":"2026-05-16T21:19:41.011148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Azitra Q3 net loss widens to $2.8M; cash $1.4M; first patient dosed in ATR-04 Ph1/2 trial","bullets":["Net loss of $2.8M for Q3 2025, compared to $1.0M in Q3 2024.","Cash and equivalents $1.4M as of Sept 30, 2025; raised $2.8M gross via equity line from Alumni Capital.","Dosed first patient in Phase 1/2 trial for ATR-04 targeting EGFRi-associated rash; FDA Fast Track granted.","Presented positive preclinical data for ATR-01 (ichthyosis vulgaris) at BIO-Europe.","R&D expenses $1.2M (up from $1.0M), G&A $1.6M (down from $1.9M) YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001701478-25-000051","json":"https://secwatch.observer/filing/0001701478-25-000051.json","markdown":"https://secwatch.observer/filing/0001701478-25-000051.md","text":"https://secwatch.observer/filing/0001701478-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/0001701478-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000170147825000051/aztr-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:19:41.011148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}